Advertisement


Diana D. Shi, MD, on IDH-Mutant Gliomas: De Novo Pyrmidine Synthesis Inhibitor Under Study

2021 ASTRO Annual Meeting

Advertisement

Diana D. Shi, MD, of Dana-Farber Cancer Institute and Brigham and Women’s Cancer Center, discusses studies being planned and already underway to test BAY 2402234, a de novo pyrimidine synthesis inhibitor that possibly could be used clinically to target IDH-mutant gliomas and may act as a tumor-selective radiosensitizer (Abstract 167).



Related Videos

Prostate Cancer

Benjamin Movsas, MD, on Prostate Cancer: Patient-Reported Outcomes on Radiotherapy and Androgen Suppression

Benjamin Movsas, MD, of the Henry Ford Cancer Center, discusses results from the NRG Oncology/RTOG 0815 study, which explored dose-escalated radiotherapy alone or in combination with short-term hormonal therapy for patients with intermediate-risk prostate cancer. In addition to clinical outcomes, Dr. Movsas discusses patient-reported results in the study that may help patients make informed decisions when choosing between these treatment options (Abstract 4).

Issues in Oncology

Karen M. Winkfield, MD, PhD, on Digital Health to Improve Patient Outcomes and Experience

Karen M. Winkfield, MD, PhD, of Vanderbilt University Medical Center, who co-chaired a session (PS 02) on digital health, summarizes the talks, which included ways to reduce disparities with digital innovations and the importance of patient input, especially in the form of patient-reported outcomes and experience measures. Advancing digital health, which the FDA defines as including health information technology, telemedicine, and personalized medicine, can potentially improve cancer care.

Head and Neck Cancer

Daniel J. Ma, MD, on HPV-Associated Oropharyngeal Squamous Cell Carcinoma: Comparing Longer and Shorter Courses of Radiotherapy

Daniel J. Ma, MD, of the Mayo Clinic Alix School of Medicine, discusses results from a phase III study of patients with HPV-associated oropharyngeal squamous cell carcinoma. Comparing a 2-week course of de-escalated adjuvant radiation therapy with the standard 6-week course, investigators found that the shorter treatment appeared to have less toxicity, higher quality of life, and similar disease control as the longer standard-of-care treatment (Abstract LBA1).

Prostate Cancer

Amar U. Kishan, MD, on Prostate Cancer: Impact of Androgen-Deprivation Therapy With Radiotherapy

Amar U. Kishan, MD, of the University of California, Los Angeles, discusses findings from a meta-analysis of clinical trials in patients with localized prostate cancer. The phase III results suggest that the use of androgen-deprivation therapy (ADT) or prolonged adjuvant ADT with radiotherapy may benefit patients with localized prostate cancer. Further biomarkers are needed to better personalize treatment intensification (Abstract 8).

Breast Cancer

Yongbae Kim, MD, on Elective Internal Mammary Node Irradiation in Women With Node-Positive Breast Cancer: Results of a Randomized Phase III Trial

Yongbae Kim, MD, of the Yonsei Cancer Center and Yonsei University College of Medicine, discusses findings that showed the use of internal mammary area irradiation (IMNI) in regional nodal irradiation did not significantly improve disease-free survival for women with node-positive breast cancer. However, patients with medially or centrally located tumors may be considered for treatment with IMNI (Abstract 2).

Advertisement

Advertisement



Advertisement